FMFarzaneh Moammer

Farzaneh Moammer

*This is an algorithmically generated author record based on publicly available information.

Farzaneh Moammer has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictors of glomerular IgA immunostaining patterns and disease progression in IgA nephropathy patients; a 13-year study of clinical and morphological features of renal biopsies

    by Ali Rastegar-Kashkouli, Pourya Yousefi, Mohsen Jafari, Zahra Pirasteh, Azadeh Tafakori, Amir Mohammad Taravati, Farzaneh Moammer, Seyedeh Ghazal Shahrokh, Dordaneh Rastegar, Hossein Mardanparvar, et al.

    Introduction: IgA nephropathy (IgAN) is a common primary glomerulonephritis with highly heterogeneous clinical and histopathological features. The MEST-C scoring system has been developed to improve prognostic assessment but lacks elements related to immunostaining study. Objectives: This study aimed to investigate the association between the immunofluorescence (IF) deposits’ patterns of IgA (mesangiocapillary versus pure mesangial) with demographic, clinical, biochemical, and morphological parameters of MEST-C classification in IgAN patients. Patients and Methods: This retrospective, cross-sectional study was conducted on 268 biopsy-proven cases of IgAN from July 2009 to July 2022 at a single laboratory in Isfahan in Iran. The demographic, clinical, and laboratory data including age, gender, serum creatinine, and proteinuria were collected from the biopsy request forms. The morphological parameters of MEST-C classification and IF study patterns were collected from the biopsy reports. Results: The average age of all patients was 37.7 ± 13.47 years, with 67% being males. The mean serum creatinine and proteinuria levels were 1.43 mg/dL and 1730.94 mg/day, respectively. MEST-C score analysis revealed that 171 patients (63.8%) had mesangial expansion (M1), while 105 patients (39.2%) exhibited endocapillary hypercellularity (E1). Additionally, segmental glomerulosclerosis (S1) and tubular atrophy/interstitial fibrosis (T1 and T2) was observed in 160 biopsy samples (59.7%). Moreover, crescent (C) formation was noted in 76 (28.4%) of biopsies. Data analysis using univariate logistic regression demonstrated that E, T, and C on morphology, complement C3, IgG, IgM deposits on IF, and the total MEST score were all associated with an increased risk for mesangiocapillary deposits of IgA. However, using the multivariate method, the results indicated that only the total MEST score (OR: 2.4), presence of crescent (OR: 3.22), presence of endocapillary hypercellularity (OR: 4.86), tubular atrophy/interstitial fibrosis grade II (OR: 34.4), and IgG deposition (OR: 3.37) were independent risk factors for mesangiocapillary deposits of IgA. Conclusion: The total MEST score is significantly higher in mesangiocapillary patterns. Furthermore, the presence of E1, T2, and C1-2 morphological parameters of the updated Oxford classification in renal biopsies are independent risk factors for IgA mesangiocapillary deposits. Hyperactivation of immunoglobulins and the complement system appears to contribute to mesangial-capillary proliferation.

  • Open Access

    Investigating the potential association between hypertension and cancer: unveiling onco-hypertension as an innovative concept

    by Mohsen Jafari, Ali Rastegar-Kashkouli, Pourya Yousefi, Farzaneh Moammer, Amir Mohammad Taravati, Seyedeh Ghazal Shahrokh, Koushan Rostami, Mohammad Reza Jafari

    Hypertension and cancer show a possible association, with hypertension being a result of cancer and its treatments and also serving as a potential risk factor for the development of cancer. The term "onco-hypertension" describes the presence of hypertension in individuals who have been diagnosed with cancer. Among individuals with cancer, hypertension is the most common coexisting medical condition, occurring in 38% of cases. Cancer-related hypertension involves various mechanisms, including tumor-related factors, coexisting conditions, renal dysfunction, hormonal abnormalities, and stress-related inflammation. Cancer treatments like chemotherapy-targeted therapies and immunotherapies have the potential to influence the regulation of blood pressure through the renin-angiotensin-aldosterone system (RAAS), sodium balance, and fluid retention. Epidemiological studies suggest a potential link between hypertension and specific types of cancer, although the exact reasons and underlying mechanisms remain uncertain. Antihypertensive medications have varying associations with cancer risk. Diuretics are linked to renal cell carcinoma (RCC), thiazide medications to squamous cell carcinoma (SCC), and angiotensin-converting enzyme (ACE) inhibitors to a potential increased risk of lung cancer. However, studies on angiotensin receptor blockers (ARBs) show inconclusive results. Managing onco-hypertension may require pharmacological interventions in addition to lifestyle modifications. Antihypertensive medications commonly used include ACE inhibitors, ARBs, diuretics, calcium channel blockers, and beta-blockers. Factors such as overall health, cancer stage, concomitant medications, treatment interactions, efficacy, tolerability, and side effects guide medication selection.

  • Open Access

    Relationship Between Ankylosing Spondylitis and Cerebrovascular Disorders: A Systematic Review

    by Mohammad Mahdi Heidari, Azad Khaledi, Amir Mohammad Taravati, Ali Rastegar-Kashkouli, Farzaneh Moammer, Iman Saffar

    Cerebrovascular events are linked to ankylosing spondylitis. Accelerated atherosclerosis and endothelial dysfunction against a backdrop of inflammation have been widely blamed for the increased cerebrovascular risk in ankylosing spondylitis. The absence of a comprehensive review encouraged us to consider the link between ankylosing spondylitis and cerebrovascular diseases. Web of Science, PubMed, Medline, Scopus, and EMBASE were searched to identify studies published from 2000 to June 10, 2023. All observational and cohort studies reporting myocardial infarction or stroke and considering classic cerebrovascular risk in ankylosing spondylitis patients and healthy controls were included. Most of the included studies reported that the risk of cerebrovascular disorders was greater in ankylosing spondylitis than in the general population. Also, most studies showed that for both sexes, the prevalence of cardiovascular illnesses rose with age, and this trend was consistent across all subgroups of cardiovascular disorders. Also, most studies reported that the rate of cerebrovascular accidents in ankylosing spondylitis patients was higher than in control groups. Some studies reported that the risk of developing an ischemic stroke was higher in young patients with ankylosing spondylitis, while others did not. Our systematic analysis found that most studies agreed that ankylosing spondylitis patients had a higher risk of cerebrovascular diseases than the general population. Still, this increased risk was influenced by several factors that need further research exploration. Cite this article as: Heidari MM, Khaledi A, Taravati AM, Rastegar-Kashkouli A, Moammer F, Safari I. Relationship between ankylosing spondylitis and cerebrovascular disorders: A systematic review. Eurasian J Med. 2024;56(2):127-135.


  • Open Access

    Exosomal long non-coding RNAs: novel molecules in gastrointestinal cancers’ progression and diagnosis

    by Mohammad Roshani, Ghazaleh Baniebrahimi, Mahboubeh Mousavi, Noushid Zare, Reza Sadeghi, Reza Salarinia, Amirhossein Sheida, Danial Molavizadeh, Sara Sadeghi, Farzaneh Moammer, et al.

    Gastrointestinal (GI) cancers arise in the GI tract and accessory organs, including the mouth, esophagus, stomach, liver, biliary tract, pancreas, small intestine, large intestine, and rectum. GI cancers are a major cause of cancer-related morbidity and mortality worldwide. Exosomes act as mediators of cell-to-cell communication, with pleiotropic activity in the regulation of homeostasis, and can be markers for diseases. Non-coding RNAs (ncRNAs), such as long non-coding RNAs (lncRNAs), can be transported by exosomes derived from tumor cells or non-tumor cells. They can be taken by recipient cells to alter their function or remodel the tumor microenvironment. Moreover, due to their uniquely low immunogenicity and excellent stability, exosomes can be used as natural carriers for therapeutic ncRNAs in vivo. Exosomal lncRNAs have a crucial role in regulating several cancer processes, including angiogenesis, proliferation, drug resistance, metastasis, and immunomodulation. Exosomal lncRNA levels frequently alter according to the onset and progression of cancer. Exosomal lncRNAs can therefore be employed as biomarkers for the diagnosis and prognosis of cancer. Exosomal lncRNAs can also monitor the patient’s response to chemotherapy while also serving as potential targets for cancer treatment. Here, we discuss the role of exosomal lncRNAs in the biology and possible future treatment of GI cancer.